Systematic review of therapeutic interventions in human prion disease

Neurology

Volumn 70, Issue 15, 2008, Pages 1272-1281

  Stewart, Lesley A ^a,d   Rydzewska, Larysa H M ^a   Keogh, Geraldine F ^b   Knight, Richard S G ^c  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b National Prion Clinic   (United Kingdom)

^c National CJD Surveillance Unit   (United Kingdom)

^d UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMANTADINE; AMPHOTERICIN; ANTIOXIDANT; CLOMIPRAMINE; DAPSONE; DOXYCYCLINE; ETIRACETAM; FLUPIRTINE; INTERFERON; MEPACRINE; PENTOSAN POLYSULFATE; PHENYTOIN; PLACEBO; SIMVASTATIN; TOPIRAMATE; VENLAFAXINE; VIDARABINE; VITAMIN;

ABSENCE OF SIDE EFFECTS; ARTICLE; BONE MARROW APLASIA; CLINICAL STUDY; CLINICAL TRIAL; COGNITIVE DEFECT; CREUTZFELDT JAKOB DISEASE; CYTOLYTIC HEPATITIS; DETERIORATION; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG ERUPTION; DRUG USE; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; LOADING DRUG DOSE; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; OUTCOME ASSESSMENT; PIGMENT DISORDER; PRION DISEASE; PRIORITY JOURNAL; PSORIASIS; PSYCHOSIS; SIDE EFFECT; SURVIVAL; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; URTICARIA;

EID: 42049122359     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000308955.25760.c2     Document Type: Review

References (53)

1. McKintosh E, Tabrizi SJ, Collinge J. Prion diseases. J Neurovirol 2003;9:183-193.
2. World Health Organization. WHO manual for surveillance of human transmissible spongiform encephalopathies including variant Creutzfeldt-Jakob disease. 2003. Available at: whqlibdoc.who.int/publications/2003/9241545887.pdf.
3. Ladogana A, Puopolo M, Croes EA, et al. Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. Neurology 2005;64:1586-1591.
4. Korth C, Peters PJ. Emerging pharmacotherapies for Creutzfeldt-Jakob disease. Arch Neurol 2006;63:497-501.
5. Heinemann U, Krasnianski A, Meissner B, et al. Creutzfeldt-Jakob disease in Germany: a prospective 12-year surveillance. Brain 2007;130:1350-1359.
6. Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996;347:921-925.
7. Spencer MD, Knight RS, Will RG. First hundred cases of variant Creutzfeldt-Jakob disease: retrospective case note review of early psychiatric and neurological features. BMJ 2002;324:1479-1482.
8. MacLeod MA. Potential treatments and treatment strategies in Creutzfeldt-Jakob disease. Idrugs 2003;6:345-350.
9. Trevitt CR, Collinge J. A systematic review of prion therapeutics in experimental models. Brain 2006;129:2241-2265.
10. Egger M, Davey Smith G, Schneider M. Systematic reviews of observational studies. In Systematic reviews in healthcare. Meta-analysis in context. BMJ books 2001:211-227.
11. World Health Organization. WHO Consultation on the Revision of the Surveillance Case Definition for Variant Creutzfeldt-Jakob Disease (vCJD). 17 May 2001. Available at: whqlibdoc.who.int/hq/2002/WHO_CDS_CSR_EPH_2001.5.pdf.
12. David AS, Grant R, Ballantyne JP. Unsuccessful treatment of Creutzfeldt-Jakob disease with acyclovir. Lancet 1984;1:512-513.
13. Newman PK. Acyclovir in Creutzfeldt-Jakob disease. Lancet 1984;1:793.
14. Taratuto AL, Piccardo P, Leiguarda R, et al. Creutzfeldt-Jakob disease. Report of 10 neuropathologically-verified cases in Argentina. Medicina 1989;49:293-303.
15. Kovanen J. Clinical characteristics of familial and sporadic Creutzfeldt-Jakob disease in Finland. Acta Neurol Scand 1993;87:469-474.
16. Neri G, Figa-Talamanca L, Di Battista GC, Lo Russo F. Amantadine in Creutzfeldt-Jakob disease. Review of the literature and case contribution. Riv Neurobiol 1984;30:47-56.
17. Terzano MG, Montanari E, Calzetti S, Mancia D, Lechi A. The effect of amantadine on arousal and EEG patterns in Creutzfeldt-Jakob disease. Arch Neurol 1983;40:555-559.
18. Braham J. Jakob-Creutzfeldt disease: treatment by amantadine. BMJ 1971;4:212-213.
19. Sanders WL, Dunn TL. Creutzfeldt-Jakob disease treated with amantadine: a report of two cases. J Neurol Neurosurg Psychiatry 1973;36:581-584.
20. Scully RE, Galdabini JJ, McNeely BU. Case records of the Massachusetts General Hospital. N Engl J Med 1980;303:1162-1171.
21. Herishanu Y. Antiviral drugs in Jakob-Creutzfeldt disease. J Am Geriatr Soc 1973;21:229-231.
22. Ratcliffe J, Rittman A, Wolf S, Verity MA. Creutzfeldt-Jakob disease with focal onset unsuccessfully treated with amantadine. Bull LA Neurol Soc 1975;40:18-20.
23. Sanders WL. Creutzfeldt-Jakob disease treated with amantadine. J Neurol Neurosurg Psychiatry 1979;42:960-961.
24. Furlow TWJ, Whitley RJ, Wilmes FJ. Repeated suppression of Creutzfeldt-Jakob disease with vidarabine. Lancet 1982;2:564-565.
25. Haik S, Brandel JP, Salomon D, et al. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology 2004;63:2431-2435.
26. Nakajima M, Yamada T, Kusuhara T, et al. Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 2004;17:158-163.
27. Bertrand A, Martinez-Almoyna L, De Broucker T. Hereditary Creutzfeldt-Jakob disease caused by a mutation at codon 200. Revue Neurol 2005;161:351-354.
28. Martinez-Lage JF, Rabano A, Bermejo J, et al. Creutzfeldt-Jakob disease acquired via a dural graft: failure of therapy with quinacrine and chlorpromazine. Surg Neurol 2005;64:542-545.
29. Wroe SJ, Pal S, Siddique D, et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet 2006;368:2061-2067.
30. Kennedy AM, Walker S, Darbyshire J, Collinge J. The MRC Prion-1 trial: development of a protocol to evaluate quinacrine and other potential therapeutics for human prion disease. Presented at Prion Diseases: From Basic Research to Intervention Concepts. Oct 8-10, 2003; Munich. Abstract BR-115.
31. Scoazec JY, Krolak-Salmon P, Casez O, et al. Quinacrine-induced cytolytic hepatitis in sporadic Creutzfeldt-Jakob disease. Ann Neurol 2003;53:546-547.
32. Kobayashi Y, Hirata K, Tanaka H, Yamada T. Quinacrine administration to a patient with Creutzfeldt-Jakob disease who received a cadaveric dura mater graft: an EEG evaluation. Rinsho Shinkeigaku Clin Neurol 2003;43:403-408.
33. Biacabe AG, Peoc'h K, Delasnerie-Laupretre N, et al. Mepcrine therapy in CJD patients does not affect CSF 14-3-3 accumulation. Presented at: New Perspectives for Prion Therapies; Dec 1-3, 2002; Paris. Abstract P-24.
34. Benito-Leon J. Combined quinacrine and chlorpromazine therapy in fatal familial insomnia. Clin Neuropharmacol 2004;27:201-203.
35. Satoh K, Shirabe S, Eguchi K, et al. Toxicity of quinacrine can be reduced by co-administration of p-glycoprotein inhibitor in sporadic Creutzfeldt-Jakob disease. Cell Molec Neurobiol 2004;24:873-875.
36. Whittle IR, Knight RS, Will RG. Unsuccessful intraventricular pentosan polysulphate treatment of variant Creutzfeldt-Jakob disease. Acta Neurochir 2006;148:677-679.
37. Parry A, Baker I, Stacey R, Wimalaratna S. Long term survival in a patient with variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulphate. J Neurol Neurosurg Psychiatry 2007;78:733-734.
38. Todd NV, Morrow J, Doh-ura K, et al. Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt-Jakob disease. J Infect 2005;50:394-396.
39. Rainov NG, Tsuboi Y, Krolak-Salmon P, Vighetto A, Doh-Ura K. Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate? Exp Opin Biol Ther 2007;7:713-726.
40. Masullo C, Macchi G, Xi YG, Pocchiari M. Failure to ameliorate Creutzfeldt-Jakob disease with amphotericin B therapy. J Infect Dis 1992;165:784-785.
41. Kovanen J, Haltia M, Cantell K. Failure of interferon to modify Creutzfeldt-Jakob disease. BMJ 1980;280:902.
42. Dervaux A, Vicart S, Lopes F, Le Borgne MH. Psychiatric manifestations of a new variant of Creutzfeldt-Jakob disease: apropos of a case. Encephale 2001;27:194-197.
43. Otto M, Cepek L, Ratzka P, et al. Efficacy of flupirtine on cognitive function in patients with Creutzfeldt-Jakob disease. Neurology 2004;62:714-718.
44. Otto M, Cepek L, Mollenhauer B, et al. Investigation of flupirtine and dapsone on cognitive function in patients with CJD. Presented at First International Conference of the European Network of Excellence (NeuroPrion). May 24-28, 2004; Paris. Poster 53.
45. Imperiale D, Bortolotto S, Cucatto A, Schiffer P, Cassano D, Buffa C. Levetiracetam control of myoclonus in a patient with Creutzfeldt-Jakob disease. Eur Neurol 2003;49:189-190.
46. Floel A, Reilmann R, Frese A, Ludemann P. Anticonvulsants for Creutzfeldt-Jakob disease? Lancet 2003;361:224.
47. Drisko JA. The use of antioxidants in transmissible spongiform encephalopathies: a case report. J Am Coll Nutr 2002;21:22-25.
48. Pocchiari M, Puopolo M, Croes EA, et al. Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Brain 2004;127:2348-2359.
49. Esmonde TG, Will RG. Creutzfeldt-Jakob disease in Scotland and Northern Ireland 1980 -1989. Scottish Med J 1992;37:181-184.
50. Chalmers TC, Koff RS, Grady G. A note on fatality in serum hepatitis. Gastroenterology 1965;49:22-26.
51. Will RG, Matthews WB. A retrospective study of Creutzfeldt-Jakob disease in England and Wales 1970-79. I: Clinical features. J Neurol Neurosurg Psychiatry 1984;47:134-140.
52. Otto M, Cepek L, Ratzka P, et al. Efficacy of flupirtine on cognitive function in patients with Creutzfeldt-Jakob-disease. Presented at New Perspectives for Prion Therapies. Dec 1-3, 2002; Paris. Abstract O-25.
53. Haik S, Brandel JP, Salomon D, et al. Clinical and neuropathological features of CJD patients treated with quinacrine in France. Presented at Prion Diseases: From Basic Research to Intervention Concepts. Oct 8-10, 2003; Munich. Abstract IV-26.